SCHEMBL29784265

SCHEMBL29784265

O=C(O)c1ccc2[nH]c(-c3ccccc3)cc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.77
SENP8 Q96LD8 1/20 0.77
SENP7 Q9BQF6 1/20 0.77
SENP6 Q9GZR1 1/20 0.77
F2 P00734 3/20 0.68
PPARG P37231 1/20 0.61
CYP19A1 P11511 4/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
KDM4E B2RXH2 2/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.58
KMT2A Q03164 2/20 0.58
ALDH1A1 P00352 1/20 0.58
LMNA P02545 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
F10 P00742 2/20 0.57
PLG P00747 2/20 0.57
PLAU P00749 2/20 0.57
PRSS1 P07477 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979496 1.00 CASP3 (0.77) CASP3SENP8SENP7SENP6F2
SCHEMBL23717137 0.87 F2 (0.64) CASP3SENP8SENP7SENP6F2
SCHEMBL11688369 0.87 F2 (0.64) CASP3SENP8SENP7SENP6F2
SCHEMBL29941485 0.87 CASP3 (1.00) CASP3SENP8SENP7SENP6F2
SCHEMBL3704691 0.87 CASP3 (1.00) CASP3SENP8SENP7SENP6F2
SCHEMBL11565448 0.86 CHEK2 (0.67) CASP3SENP8SENP7SENP6F2
SCHEMBL4334503 0.86 CASP3 (0.57) CASP3SENP8SENP7SENP6F2
SCHEMBL164956 0.86 CASP3 (0.57) CASP3SENP8SENP7SENP6F2
SCHEMBL693160 0.86 F2 (0.58) CASP3SENP8SENP7SENP6F2
SCHEMBL11563588 0.86 CASP3 (0.57) CASP3SENP8SENP7SENP6F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082646-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF MITOIMMUNE THERAPEUTICS INC. (KR) 2025-03-13 US disclosed
EP-4470541-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF MitoImmune Therapeutics Inc. (KR) 2024-12-04 EP disclosed
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082646-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP19A1, NR5A1, CYP11A1 CASP3 2183/4885SENP8 1107/4885SENP7 494/4885
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG CASP3 4280/4885SENP8 4307/4885SENP7 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.